{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000140","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.444894+00:00","generated_at":"2026-05-16T12:43:39.882220+00:00","sec_items":["5.02","5.05","7.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise","bullets":["Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.","Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.","Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.","CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.","Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000140","json":"https://secwatch.observer/filing/0001453687-25-000140.json","markdown":"https://secwatch.observer/filing/0001453687-25-000140.md","text":"https://secwatch.observer/filing/0001453687-25-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/0001453687-25-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/rnac-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:43:39.882220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}